<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>DRREDDY on Financial Report Insights</title>
    <link>https://reports.muthu.co/tags/drreddy/</link>
    <description>Recent content in DRREDDY on Financial Report Insights</description>
    <generator>Hugo</generator>
    <language>en-us</language>
    <lastBuildDate>Wed, 29 Jan 2025 20:27:00 +0000</lastBuildDate>
    <atom:link href="https://reports.muthu.co/tags/drreddy/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>Dr Reddys Laboratories Ltd - Jan 2025 Earnings Call Transcript Analysis</title>
      <link>https://reports.muthu.co/posts/dr-reddys-laboratories-ltd---jan-2025-earnings-call-transcript-analysis/</link>
      <pubDate>Wed, 29 Jan 2025 20:27:00 +0000</pubDate>
      <guid>https://reports.muthu.co/posts/dr-reddys-laboratories-ltd---jan-2025-earnings-call-transcript-analysis/</guid>
      <description>&lt;h2 class=&#34;heading&#34; id=&#34;earnings-call-transcript-analysis-report&#34;&gt;&#xA;  Earnings Call Transcript Analysis Report&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#earnings-call-transcript-analysis-report&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h2&gt;&#xA;&lt;h2 class=&#34;heading&#34; id=&#34;financial-performance&#34;&gt;&#xA;  Financial Performance&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#financial-performance&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h2&gt;&#xA;&lt;p&gt;&lt;strong&gt;Key Financial Metrics:&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;&lt;strong&gt;Consolidated Revenues:&lt;/strong&gt; Rs. 8,359 crores ($977 million), up 16% YoY and 4% QoQ.&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Includes Rs. 605 crores from acquired Nicotine Replacement Therapy (NRT) business.&lt;/li&gt;&#xA;&lt;li&gt;Excluding NRT, underlying revenue growth was 7.5% YoY and a decline of 3% QoQ.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Consolidated Gross Profit Margin:&lt;/strong&gt; ~59% (up 19 bps YoY, down 91 bps QoQ).&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Global Generics Gross Margin: 61.3%&lt;/li&gt;&#xA;&lt;li&gt;PSAI Gross Margin: 28.6%&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;SG&amp;amp;A Spend:&lt;/strong&gt; Rs. 2,412 crores ($282 million), up 19% YoY and 5% QoQ. As % to sales: 28.9%.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;R&amp;amp;D Spend:&lt;/strong&gt; Rs. 666 crores ($78 million), up 20% YoY, down 8% QoQ. As % to sales: 8.0%.&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Guidance: Expected to be in the range of 8.5-9% for the full fiscal year.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;EBITDA (including other income):&lt;/strong&gt; Rs. 2,298 crores ($269 million), up 9% YoY, flat QoQ.&#xA;&lt;ul&gt;&#xA;&lt;li&gt;EBITDA Margin: 27.5% (down 176 bps YoY, down 95 bps QoQ).&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Profit Before Tax (PBT):&lt;/strong&gt; Rs. 1,874 crores ($219 million). PBT as % of revenues: 22.4%.&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Includes PBT from NRT business of Rs. 124 crores (this excludes interest allocation, only includes amortization).&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Effective Tax Rate (ETR):&lt;/strong&gt; 25.1%.&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Guidance: Normalized ETR expected around 25%.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Profit After Tax (PAT attributable to equity holders):&lt;/strong&gt; Rs. 1,413 crores ($165 million), up 2% YoY, up 13% QoQ. As % of revenues: 17%.&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Reported EPS:&lt;/strong&gt; Rs. 16.94 (post stock split and NCI).&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Operating Working Capital:&lt;/strong&gt; Rs. 12,782 crores ($1.49 billion).&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Capex Cash Outflow:&lt;/strong&gt; Rs. 709 crores ($83 million).&lt;/li&gt;&#xA;&lt;li&gt;&lt;strong&gt;Net Cash Surplus:&lt;/strong&gt; Rs. 1,603 crores ($187 million).&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;strong&gt;Comparisons &amp;amp; Trends:&lt;/strong&gt;&lt;/p&gt;</description>
    </item>
    <item>
      <title>Dr Reddys Laboratories Ltd:Annual Report 2023-24 Analysis</title>
      <link>https://reports.muthu.co/posts/dr-reddys-laboratories-ltdannual-report-2023-24-analysis/</link>
      <pubDate>Tue, 02 Jul 2024 19:41:41 +0000</pubDate>
      <guid>https://reports.muthu.co/posts/dr-reddys-laboratories-ltdannual-report-2023-24-analysis/</guid>
      <description>&lt;h2 class=&#34;heading&#34; id=&#34;dr-reddys-laboratories-ltd-a-comprehensive-overview&#34;&gt;&#xA;  Dr. Reddy&amp;rsquo;s Laboratories Ltd.: A Comprehensive Overview&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#dr-reddys-laboratories-ltd-a-comprehensive-overview&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h2&gt;&#xA;&lt;h3 class=&#34;heading&#34; id=&#34;about-the-company&#34;&gt;&#xA;  About the Company&#xA;  &lt;a class=&#34;anchor&#34; href=&#34;#about-the-company&#34;&gt;#&lt;/a&gt;&#xA;&lt;/h3&gt;&#xA;&lt;p&gt;&lt;strong&gt;Year of Establishment and Founding History:&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;p&gt;Dr. Reddy&amp;rsquo;s Laboratories Ltd. was founded in 1984 by Dr. Kallam Anji Reddy.&lt;/p&gt;&#xA;&lt;p&gt;&lt;strong&gt;Headquarters Location and Global Presence:&lt;/strong&gt;&lt;/p&gt;&#xA;&lt;ul&gt;&#xA;&lt;li&gt;Headquarters: Hyderabad, Telangana, India&lt;/li&gt;&#xA;&lt;li&gt;Global Presence: Dr. Reddy&amp;rsquo;s operates in markets across the globe, including North America, Europe, India, Russia, and other emerging markets. They have a significant presence in the US generics market.&lt;/li&gt;&#xA;&lt;/ul&gt;&#xA;&lt;p&gt;&lt;strong&gt;Company Vision and Mission:&lt;/strong&gt;&lt;/p&gt;</description>
    </item>
  </channel>
</rss>
